"The U.S. Food and Drug Administration today approved Vimizim (elosulfase alfa), the first FDA-approved treatment for Mucopolysaccharidosis Type IVA (Morquio A syndrome). Morquio A syndrome is a rare, autosomal recessive lysosomal storage disease "...
(Generic versions may still be available.)
- Patient Information:
Details with Side Effects
DOSAGE AND ADMINISTRATION
One tablet (60 mg) twice daily for adults and pediatric patients 12 years and older.
USE OF DOSES IN EXCESS OF 60 MG B.I.D. IS NOT RECOMMENDED BECAUSE OF THE INCREASED POTENTIAL FOR QT INTERVAL PROLONGATIONS AND ADVERSE CARDIAC EVENTS. (See BOXED WARNING).USE OF TERFENADINE IN PATIENTS WITH SIGNIFICANT HEPATIC DYSFUNCTION AND IN PATIENTS TAKING KETOCONAZOLE, ITRACONAZOLE, CLARITHROMYCIN, ERYTHROMYCIN OR TROLEANDOMYCIN IS CONTRAINDICATED. (See CONTRAINDICATIONS, WARNINGS, and DRUG INTERACTIONS).
Removed from market 1998
60 mg tablets in bottles of 100.
60 mg tablets in bottles of 500.
Tablets are round, white, and debossed "SELDANE (terfenadine (removed from market 1998)) ". Store tablets at controlled room temperature (59-86°F) (15-30°C). Protect from exposure to temperatures above 104°F (40°C) and moisture.
Last reviewed on RxList: 12/8/2004
This monograph has been modified to include the generic and brand name in many instances.
Additional Seldane Information
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.
Find out what women really need.